MaxCyte Sinks 10% as $151.8M Akron Bio Buyout Dilutes Shareholders
MXCT sits 80% above its 52-week low of $0.643 on elevated volume (2.7× avg).
Summary
MaxCyte is paying $151.8M for Akron BioProducts — $105.0M cash, roughly 20.6M new shares worth about $26.8M, plus $20.0M in guaranteed deferred payments split across January 2028 and January 2029. The stock fell more than 10% Tuesday, and the dilution is the obvious reason: the share issuance is large next to a company trading around $1.16 with a market cap near $119M. Akron is projected to bring $28M in revenue and $7M-$8M of adjusted EBITDA this year, which management says accelerates the path to profitability once the deal closes later this year. The deal lands alongside better-than-expected Q3 results and a raised full-year revenue outlook to at least $34.5M versus $32.2M consensus, so the selloff is about deal terms and dilution rather than the core business. Watch the closing later this year and whether the combined entity delivers the promised EBITDA.
At the time of this announcement, MXCT was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $119.2M. The 52-week trading range was $0.64 to $1.81. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.